Acadian Asset Management’s Prelude Therapeutics PRLD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$3.28M Buy
842,984
+231,625
+38% +$1.14M ﹤0.01% 934
2026
Q2
$3.25M Buy
611,359
+99,840
+20% +$435K ﹤0.01% 924
2026
Q1
$1.75M Sell
511,519
-24,184
-5% -$63.4K ﹤0.01% 998
2025
Q4
$1.55M Sell
535,703
-4,862
-0.9% -$8.2K ﹤0.01% 985
2025
Q3
$777K Hold
540,565
– – ﹤0.01% 1115
2025
Q2
$436K Buy
540,565
+11,238
+2% +$9.7K ﹤0.01% 1166
2025
Q1
$405K Buy
529,327
+43,946
+9% +$41K ﹤0.01% 1117
2024
Q4
$617K Buy
485,381
+411,238
+555% +$546K ﹤0.01% 1032
2024
Q3
$152K Buy
74,143
+52,033
+235% +$241K ﹤0.01% 1459
2024
Q2
$83K Hold
22,110
– – ﹤0.01% 1559
2024
Q1
$104K Buy
22,110
+6,615
+43% +$25.7K ﹤0.01% 1281
2023
Q4
$65K Buy
15,495
+8,472
+121% +$25.8K ﹤0.01% 1428
2023
Q3
$21K Buy
+7,023
New +$26.4K ﹤0.01% 1540

Other funds holding PRLD

Acadian Asset Management's PRLD Position: Q3 2026 in Review

Acadian Asset Management increased its Prelude Therapeutics (PRLD) stake by 38% in Q3 2026, buying an estimated $1.14M and bringing the position to 842,984 shares worth $3.28M. The position accounts for ﹤0.01% of the portfolio, ranked #934.

Acadian Asset Management first reported a position in PRLD in Q3 2023 and has held it in 13 quarters since. 92 funds tracked by Wall St. Rank hold PRLD as of Q3 2026.

  • Acadian Asset Management held 842,984 shares of Prelude Therapeutics worth $3.28M as of Q3 2026.
  • Acadian Asset Management bought 231,625 Prelude Therapeutics shares in Q3 2026, an estimated $1.14M.
  • Prelude Therapeutics made up ﹤0.01% of Acadian Asset Management's portfolio in Q3 2026, its #934 holding.
  • Acadian Asset Management first reported a position in Prelude Therapeutics in Q3 2023 and has held it in 13 quarters since.
  • 92 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q3 2026.

Based on Acadian Asset Management's 13F filing for Q3 2026, filed 9 Nov 2026.